Interpace Diagnostics Reports Purchase Of Cancer Genetics' Biopharma Services Unit; Ampersand Capital Will Invest $27M In Interpace In 2 Tranches Of Newly Issued Convertible Preferred Stock
Benzinga Newsdesk